Medsolve Dynamics

The CY 2027 OPPS proposed rule puts the 340B drug spread underneath hospital theranostics programs on the table. Two drugs carry the category, Pluvicto and Lutathera, and for many programs the spread is what made the line lucrative. This episode covers the discipline: nobody tears up a program on a proposed rule, and nobody signs capital before checking whether the plan still works if the rule sti...

Parts lead time and field-engineer coverage, not the uptime percentage in your contract, decide how long a LINAC is actually down. A vendor-side look at how service coverage models are built around the vendor's cost, not your schedule, and what that costs your throughput and margin. LINAC downtime, service coverage, parts logistics, field engineer, uptime SLA, throughput, time toxicity. medsolvedy...

A radiation oncology service contract that quotes the same rate on a one-year-old LINAC and a twenty-year-old one was never priced on the cost to serve the machine. It was priced to anchor you. How to make a LINAC service price prove it is tied to cost. LINAC service contract, service pricing, capital negotiation, vendor negotiation, AMAC, purchasing framework. medsolvedynamics.com team@medsolvedy...

Your first capital negotiation is against someone who runs forty a year. This explains where the vendor puts the leverage and how a new administrator levels the field. New administrator, capital negotiation, vendor meeting, supervision coverage, radiation oncology.

A percentage off a list price the vendor set themselves tells you very little. This explains why the value package matters more than the discount in a LINAC capital negotiation, and what a program should structure for instead. Capital strategy, vendor quote, service contract, radiation oncology. medsolvedynamics.com team@medsolvedynamics.com

Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology. medsolvedynamics.com | team@medsolvedynamics.com #AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations

Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply. medsolvedynamics.com | team@medsolvedynamics.com #Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations

AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo. medsolvedynamics.com | team@medsolvedynamics.com   #Radiation...

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor...

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affe...

Most rad onc programs walk into a service contract renewal with no independent numbers on the table. The vendor brings their performance data. The program nods. The renewal runs the vendor's direction. The gap is not in the contract language. It is in the measurement asymmetry. Five metrics the vendor tracks and the program rarely does. Uptime delivered against contracted spec. Response time again...

At ESTRO 2026, United Imaging showed a CE-marked uRT-linac 506c on the show floor. Diagnostic-CT integrated with a linear accelerator on a single platform. Online adaptive radiotherapy positioned without an MR-linac, without a third-party planning system, and without RaySearch. Reported as CE marked in Europe. Not yet in the US market. Capital decisions in flight in the US in 2026 are not changing...

Most rad onc programs sitting on soft Q2 numbers are looking outside the building for offsetting revenue. The infrastructure for radioligand therapy is already inside the building, and a Jefferson-authored paper accepted by Practical Radiation Oncology in May 2026 puts the 340B-eligible hospital gross margin at roughly $101,000 per Pluvicto patient over a full course. The same paper names why prog...

From 20 years on the vendor side of oncology software sales, the one question that exposes the AI price premium baked into software renewal quotes in 2026. Treatment planning systems, contouring software, registry products, SaaS modules. The AI features were priced higher than the same software would have priced two years ago. Get the unbundled price. medsolvedynamics.com | team@medsolvedynamics.c...

A vendor-side story Yoel Bakas has watched play out dozens of times in radiation oncology. A software demo runs without anyone asking what is actually broken in the customer's workflow. The tool gets relabeled AI-enabled a year later. Until the customer understands what is broken, it does not matter what the tool is. AI in radiation oncology, workflow design, vendor evaluation, capital decision. m...

From 20 years on the vendor side of LINAC capital and service negotiations, the data point most radiation oncology programs do not see with the same precision the vendor sees it: their own unbooked machine hours. Every unbooked hour is a fixed cost paid for and not recovered. The 15-minute utilization audit is the cheapest margin discipline in the 2026 reimbursement environment. medsolvedynamics.c...

Capital decisions hold up when the year-five reality is considered before the signature. They break when only year-one numbers are. From 20 years on the vendor side and now on the program side, the year-five question that protects margin through a multi-year operating commitment in radiation oncology. medsolvedynamics.com | team@medsolvedynamics.com

From 20 years on the vendor side and now on the program side, the math that wins capital approval is not the math the program runs in year two. The reimbursement environment moved more than the headline rate change. medsolvedynamics.com | team@medsolvedynamics.com

Benign disease radiation uses LINAC capacity that is already paid for in most programs. The growth question is referral pathway, not capital. From 20 years of watching programs add and grow service lines. medsolvedynamics.com | team@medsolvedynamics.com

From 20 years on the vendor side and now on the program side, the capital form decision that gets skipped on most theranostics service-line additions. Build or partner sets the next decade. With reference to Kenneth Brooks and Christine Stone’s published build case study at Wellstar Health System. medsolvedynamics.com | team@medsolvedynamics.com

Capital decisions in radiation oncology are not point-in-time decisions. The proforma that wins approval at signature is not the proforma that runs the program in year five. From 20 years on the vendor side and now on the program side, the math that protects margin through a full capital cycle. medsolvedynamics.com | team@medsolvedynamics.com

A moment from the AMAC Spring Symposium 2026 talk on the day I told a room of oncology administrators that I have watched programs lose margin on contracts I helped sell them. Plus the 17-year ROI case study. medsolvedynamics.com | team@medsolvedynamics.com

A short clip from the AMAC Spring Symposium 2026 talk on the discipline programs need to apply to every capital decision in the current environment. Forward-looking, not policy-blame. medsolvedynamics.com | team@medsolvedynamics.com

The capital case in a vendor proforma is usually solid. The operating case is rarely modeled. From 20 years on the vendor side selling these programs, here is the operational reality that shows up in year two and never lives in the original proforma. Applies to LINAC purchases, theranostics expansions, and benign disease program builds. medsolvedynamics.com | team@medsolvedynamics.com

Jeff Siupik, 35 years in oncology operations, on where volume responsibility actually belongs in a healthy program. The C-suite looks at P&L. The clinical team looks at compassionate care. Where leaders most often misallocate the volume expectation, and where it should sit instead. Full episode: https://youtu.be/9bPM8rjsv6Y medsolvedynamics.com | team@medsolvedynamics.com #RadiationOncology #O...